Design, synthesis and evaluation of 3-(imidazol- 1-ylmethyl)indoles as antileishmanial agents. Part II

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 24, Issue 5, 2009, Pages 1067-1075

  Giraud, Francis ^a   Loge, Cedric ^a   Pagniez, Fabrice ^a   Crepin, Damien ^a   Barres, Sophie ^a   Picot, Carine ^a   Le Pape, Patrice ^a   Le Borgne, Marc ^a,b  

^a UNIVERSITÉ DE NANTES   (France)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

3 (imidazol 1 ylmethyl)indoles; Antileishmanial agents; Craig diagram; Leishmania mexicana; QSAR

Indexed keywords

1 BENZYL 3 (IMIDAZOL 1 YLMETHYL)INDOLE DERIVATIVE; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIPROTOZOAL ACTIVITY; ARTICLE; DRUG DESIGN; DRUG SYNTHESIS; HYDROPHOBICITY; LEISHMANIA MEXICANA; NONHUMAN; PRIORITY JOURNAL; PROMASTIGOTE; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

LEISHMANIA MEXICANA;

EID: 74549174782     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.1080/14756360802610795     Document Type: Article

References (24)

1. For more details on leishmaniasis see the following website location: http://www.who.int/tdr/publications/publications/pr17.htm.
2. Davies CR, Kaye P, Croft SL, Sundar S. Br Med J 2003; 326:377-382.
3. Blum J, Desjeux P, Schwartz E, Beck B, Hatz C. J Antimicrob Chemother 2004; 53:158-166.
4. Mishra J, Saxena A, Singh S. Curr Med Chem 2007; 14:1153-1169.
5. Yardley V, Croft SL. Int J Antimicrob Agents 2000; 13:243-248.
6. Mittal MK, Rai S, Ashutosh R, Gupta S, Sundar S, Goyal N. Am J Trop Med Hyg 2007; 76:681-688.
7. Basselin M, Denise H, Coombs GH, Barrett MP. Antimicrob Agents Chemother 2002; 46:3731-3738.
8. Marchand P, Le Borgne M, Na YM, Pagniez F, Abdala H, Le Baut G, Le Pape P. J Enz Inhib Med Chem 2002; 17:353-358.
9. Na YM, Lebouvier N, Le M, Pagniez F, Alvarez N, Le Pape P, Le Baut G. J Enz Inhib Med Chem 2004; 19:451-457.
10. Pagniez F, Abdala H, Marchand P, Le Borgne M, Le Baut G, Robert- Piessard S, Le Pape P. J Enz Inhib Med Chem 2006; 21:277-283.
11. Veen M, Lang C. Biochem Soc Trans 2005; 33:1178-1181.
12. Giraud F, Logé C, Le Borgne M, Pagniez F, Na YM, Le Pape P. SAR QSAR Environ Res 2006; 17:299-309.
13. Le Borgne M, Na YM, Pagniez F, Le Baut G, Le Pape P, Abdala H. (2002) PCT Patent WO 02/24685.
14. Le Pape P, Pagniez F, Abdala H. Acta Parasitol 2002; 47:79-81.
15. Noland WE, Reich C. J Org Chem 1967; 32:828-832.
16. Robinson B. Chem Rev 1969; 69:785-797.
17. Jones CD, Winter MA, Hirsch KS, Stamm N, Taylor HM, Holden HE, Davanport JD, Krumkalns EV, Suhr RG. J Med Chem 1990; 33:416-429.
18. Ogata M. Ann NY Acad Sci 1988; 544:12-31.
19. Staab HA. Angew Chem Int Ed 1962; 1:351-367.
20. Totleben MJ, Freeman JP, Szmuszkovicz J. J Org Chem 1997; 62:7319-7323.
21. Patrick GL. Chimie pharmaceutique. 2nd ed. France: De Boeck Université; 2002, p. 274.
22. Kawasaki M, Goto M, Kawabata S, Kometani T. Tetrahedron: Asymmetry 2001; 12:585-596.
23. Kametani T, Kondoh H, Honda T, Ishizone H, Suzuki Y, Mori W. Chem Lett 1989; 18:901-904.
24. Shanks D, Amorati R, Fumo MG, Pedulli GF, Valgimigli L, Engman L. J Org Chem 2006; 71:1033-1038.